Expert Network
Scientific & Technology Advisory Board
Michael Salmans, PhD ·
Dr. Michael Salmans, PhD, is a biotechnology executive with more than 15 years of experience spanning molecular diagnostics, genomics, oncology, translational science, and product development. Throughout his career, he has led multidisciplinary teams responsible for advancing innovative diagnostic technologies from early discovery through clinical validation, regulatory engagement, and commercialization. His expertise includes next-generation sequencing (NGS), liquid biopsy, multi-omics, biomarker discovery, assay development, and clinical product strategy.
Dr. Salmans has held leadership roles at organizations including Illumina, Sequenom, GC LabTech, and Genece Health, where he directed global research and development programs and built high-performing teams across the United States and Asia.
Dr. Salmans brings a unique combination of scientific depth, operational leadership, and strategic vision. He is passionate about evaluating emerging technologies, identifying opportunities for innovation, and helping bridge the gap between scientific discovery and real-world healthcare impact. His experience working across academia, industry, and international collaborations provides a broad perspective on the evolving biotechnology landscape and the challenges faced by innovators bringing new technologies to market.
Board Formation in Progress
We are currently in the process of onboarding a limited number of advisory board members across key disciplines within the life sciences sector. Helixgate is focused on building a high-caliber advisory group composed of individuals with deep expertise and active involvement in advancing scientific discovery and real-world application.
Core Advisory Domains
Drug Discovery & Translational Science
Small molecule, biologics, and therapeutic development.
Clinical Research & Trials
Phase I–III execution, regulatory pathways, and patient outcomes.
Computational Biology & Systems
AI/ML integration, modeling, simulation, and data-driven discovery.
Biotech Infrastructure
Life science campuses, lab environments, and R&D ecosystems.
Regulatory & Compliance Strategy
FDA pathways, approvals, and global regulatory alignment.
Capital & Strategic Growth
Investment strategy, scaling biotech companies, and partnerships.
Advisory Profiles Being Considered
- Senior Scientists at leading pharmaceutical organizations
- Directors of Research & Development (R&D)
- Clinical trial and regulatory specialists
- Computational biology and AI research leaders
- Founders and executives of biotech companies
- Institutional investors in life sciences
Role of the Scientific Advisory Board
The advisory board provides strategic guidance on emerging scientific trends, validates key areas of focus within the publication, and contributes to the broader direction of Helixgate’s intelligence and research initiatives.
Members may participate in editorial guidance, topic validation, and strategic discussions surrounding the future of biotechnology and advanced systems.
By invitation and qualification only
Advisory Participation
Media Kit
Access our comprehensive media kit to understand our positioning, audience, and partnership opportunities.
- Audience positioning (biotech, pharma, investors)
- Editorial focus & Coverage style
- Sponsorship & feature opportunities
- Editorial Standards
Helixgate maintains a high standard of editorial integrity, focusing on accuracy, strategic insight, and meaningful industry contribution.
Dr. Catherine Wei
Director of Computational Biology
Stanford University
Prof. Henrik Larsson
Chair of Synthetic Biology
ETH Zurich
Dr. Amara Osei
VP of Research
Genentech
Prof. David Nakamura
Chair of Bioengineering
UC Berkeley
Prof. Nakamura is a leading figure in CRISPR technology development and genome engineering, with over 200 peer-reviewed publications.
Dr. Maria Fernandez
Chief Scientific Officer
Twist Bioscience
Prof. Robert Ashford
Director of Drug Discovery
University of Cambridge
Founding Scientific Advisory Board - In Formation
Helixgate Biotech Review is establishing a distinguished Scientific Advisory Board composed of leading scientists, biotechnology executives, research innovators, and industry experts who help guide the editorial direction and scientific integrity of our platform.
The advisory board will support Helixgate Biotech Review in identifying emerging breakthroughs across biotechnology, drug discovery, life sciences infrastructure, and next-generation scientific innovation.
Advisors will contribute expertise in areas including:
- Drug Discovery & Translational Medicine
- Molecular Biology & Genomics
- Biopharmaceutical Development
- Advanced Therapeutics
- Bioengineering & Synthetic Biology
- Life Sciences Infrastructure & Innovation Ecosystems
- Computational Biology & Scientific Platforms
Founding Advisors - Announcements Coming Soon
Helixgate Biotech Review is currently engaging respected leaders across academia, biotechnology companies, and research institutions to join the Founding Scientific Advisory Board.
Advisor announcements will be published here as appointments are finalized.
Advisory Board Participation
We welcome discussions with individuals who have significant experience in:
- Biotechnology research
- Pharmaceutical development
- Life sciences venture capital
- Scientific entrepreneurship
- Advanced therapeutic innovation
If you are interested in contributing to the Scientific Advisory Board, please contact: